このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

以前にペラブレシブの研究に登録された患者を対象とした延長研究

2026年11月6日 更新者:Novartis Pharmaceuticals

以前にペラブレシブの研究に登録された患者を対象とした非盲検多施設延長研究

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).

調査の概要

状態

募集

条件

介入・治療

詳細な説明

The study will collect and monitor ongoing efficacy information with regard to disease and survival status, as well as safety information with regard to AEs, including SAEs and AEs of special interest (AESI).

Patients are eligible to continue pelabresib treatment as long as the regimen is tolerated, and the patient does not meet any of the discontinuation criteria.

Patients who have previously received pelabresib alone or pelabresib in combination with ruxolitinib or ruxolitinib alone will continue to receive the same regimen as administered in the parent study.

There will be an eligibility check period of up to 28 days for this extension study. Patients who fulfill the inclusion and exclusion criteria are eligible for the study. After the patient willingly provides consent, eligibility will be assessed by the investigator and treatment with pelabresib can be started at the same dose and dosing schedule that was applied in the parent study in the last cycle prior to EOT unless there is need for dose adjustment due to toxicity.

A patient is considered to have completed the study after completion of all visits as defined in the Schedule of Assessments (SoA) as per protocol, including the Safety Follow-up visit and Survival Follow-up.

The Safety Follow-up period is the interval between the EOT visit and the scheduled Safety Follow-up visit, which should occur 30 days (±3 days) after the last dose of pelabresib. For patients who switch from investigational pelabresib to commercial pelabresib treatment, the Safety Follow-up period is the time from the last dose of investigational pelabresib until the first dose of commercial pelabresib. The treatment start date with commercial pelabresib will be considered the date of "early Safety Follow-up termination." All patients will be followed for AEs and SAEs for 30 days (±3 days) following the last dose of pelabresib on the extension study or until the initiation of a new anticancer therapy, whichever occurs first.

Reasonable efforts should be made to have the patient return for the Safety Follow-up visit and review any AEs that may occur during this period. If the patient cannot return to the site for the Safety Follow-up visit, then the patient should be contacted by telephone for assessment of AEs.

The end of study will occur when all parent studies have been closed with no further patients expected to be enrolled into the extension study, and all patients are either discontinued or study treatment becomes commercially available and reimbursed, or an alternate access program becomes available, whichever comes first. Prior to study completion, all patients should.have completed the Safety Follow-up visit or have been designated as lost to follow-up, died, or have withdrawn consent, whichever comes first. The sponsor reserves the right to close a study site or terminate the study at any time for any reason at the sole discretion of the sponsor.

研究の種類

介入

入学 (推定)

50

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • California
      • Los Angeles、California、アメリカ、90095
        • 募集
        • University of California LA
        • 主任研究者:
          • Gary Schiller
        • コンタクト:
    • Florida
      • Jacksonville、Florida、アメリカ、32224
        • 募集
        • Mayo Clinic Jacksonville
        • 主任研究者:
          • Candido Rivera
        • コンタクト:
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • 募集
        • Northwestern University
        • 主任研究者:
          • Brady L Stein
        • コンタクト:
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48109
        • 募集
        • Uni Of Michigan Health System
        • 主任研究者:
          • Moshe Talpaz
        • コンタクト:
    • New York
      • New York、New York、アメリカ、10021
        • 募集
        • New York Presbyterian Hospital
        • 主任研究者:
          • Joseph Scandura
        • コンタクト:
      • New York、New York、アメリカ、10029-6574
        • 募集
        • Mt Sinai Medical Center
        • 主任研究者:
          • Marina Kremyanskaya
        • コンタクト:
      • Cardiff、イギリス、CF14 4XW
        • 募集
        • Novartis Investigative Site
      • Glasgow、イギリス、G12 0YN
        • 募集
        • Novartis Investigative Site
      • London、イギリス、SE1 7EH
        • 募集
        • Novartis Investigative Site
      • Novara、イタリア、28100
        • 募集
        • Novartis Investigative Site
    • FI
      • Florence、FI、イタリア、50134
        • 募集
        • Novartis Investigative Site
    • VA
      • Varese、VA、イタリア、21100
        • 募集
        • Novartis Investigative Site
      • Amsterdam、オランダ、1081
        • 募集
        • Novartis Investigative Site
      • Antwerp、ベルギー、2030
        • 募集
        • Novartis Investigative Site
      • Bruges、ベルギー、8000
        • 募集
        • Novartis Investigative Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Able to provide signed informed consent, agreeing to all protocol and ICF requirements.

  • At least 18 years old and legally able to consent in the study's jurisdiction.

  • Previously enrolled and currently receiving pelabresib in combination with ruxolitinib or ruxolitinib alone in a parent study.

  • Demonstrating clinical benefit from pelabresib and/or ruxolitinib, as judged by the investigator.

  • Willing and able to follow all study visits, treatments, and procedures.

  • Agree to avoid pregnancy or fathering children:

    • Men: Must use highly effective contraception (≥99% effective) and avoid sperm donation from eligibility check through 94 days post-treatment.
    • Women of childbearing potential (WOCBP): Must test negative for pregnancy at eligibility, use highly effective contraception through 184 days post-treatment, undergo regular pregnancy testing, and avoid breastfeeding and oocyte donation during this period.
    • Women not of childbearing potential (surgically sterile or postmenopausal ≥12 months without other cause) are eligible.

Note: Women with amenorrhea due to chemo/radiotherapy are considered WOCBP and must use contraception.

Additional Inclusion Criteria control (placebo + ruxolitinib) group requiring pelabresib combination treatment:

  • On a stable dose of ruxolitinib for ≥8 weeks

  • Has adequate bone marrow and organ function as defined by the following local laboratory values:

    • ANC ≥ 1 × 10^9/L in the absence of growth factors for the previous 4 weeks
    • Platelet count ≥ 75 × 10^9/L in the absence of growth factors or platelet transfusions during previous 4 weeks
    • Peripheral blood blast count < 5%
    • AST and/or ALT ≤ 2.5 × ULN of the local reference interval (≤ 5 × if the elevation can be ascribed to hepatic MF involvement, e.g., presence of hepatomegaly)
    • Serum direct bilirubin < 2.0 × ULN of the local reference interval
    • Calculated or measured CrCl of ≥ 45 mL/min
  • Does not have any other concurrent medical condition that in the opinion of the investigator could compromise participation in the study

Exclusion Criteria:

  • Legally institutionalized or under judicial protection.
  • Enrolled in another interventional clinical trial (excluding the parent study).
  • History of hypersensitivity to pelabresib, its excipients, or similar drugs.
  • Significant gastrointestinal issues (e.g., active IBD, unresolved nausea/vomiting/diarrhea > Grade 1) that may affect drug absorption.
  • Any medical condition deemed unsuitable by the investigator.
  • Uncontrolled illness or condition that may compromise safety or protocol compliance.
  • Received systemic anticancer or investigational treatment (excluding parent study drug or hormonal therapy) within 2 weeks or 5 half-lives before first dose. (Hydroxyurea/anagrelide allowed up to 24 hours prior.)
  • Received hematopoietic growth factors or androgenic steroids within 4 weeks before first dose.
  • Used strong CYP3A4 inhibitors/inducers (e.g., St. John's wort) within 2 weeks before first dose. Use during treatment is prohibited.
  • Received immunosuppressive agents with systemic activity (>10 mg QD prednisone or equivalent) less than 4 weeks before the first dose of study drug in the extension study. Participants who received topical, nasal, intra-articular, inhaled, and other forms of corticosteroids without systemic activity are eligible
  • Received a live vaccination within 30 days prior to the first dose of study drug in the extension study, except for COVID-19 vaccination
  • Female participants who are pregnant, breastfeeding, or not using required contraception.
  • Male participants who do not agree to use contraception or refrain from sperm donation as specified.
  • Unwilling or unable to comply with the study protocol.

Additional Exclusion Criterion for participants receiving ruxolitinib only treatment

• Local access to commercially available and reimbursed ruxolitinib.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Pelabresib and/or ruxolitinib

Participants who have previously received pelabresib alone or pelabresib in combination with ruxolitinib or ruxolitinib alone will continue to receive the same regimen as administered in the parent study.

Additionally, the MANIFEST-2 (NCT04603495) control group (i.e., treated with placebo + ruxolitinib) patients, will be offered pelabresib combination treatment at the time of enrollment if the investigator sees any potential benefit of adding pelabresib to ruxolitinib.

Small molecule inhibitor of bromodomain and extraterminal (BET) protein

他の名前:
  • CPI-0610

Small molecule selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2.

他の名前:
  • Jakavi™/Jakafi™

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Treatment-emergent adverse events (TEAEs) and serious TEAEs
時間枠:5 years

To evaluate long-term safety in patients who are receiving pelabresib

5 years
Survival Follow-up
時間枠:5 years

Survival Follow-up consists of Survival and Leukemia-Free Survival Follow-up. All participants in the extension study will be followed up for Survival, while participants with hematological malignancies will be followed up for Survival and Leukemia-Free Survival.

5 years
Duration of Response (DoR)
時間枠:5 years

DOR defined as the time from the date of first response to the date of confirmed disease progression

5 years
Progression-free survival (PFS)
時間枠:5 years

PFS defined as the time from first dose to confirmed disease progression or death, whichever occurs first.

5 years
Leukemia-free survival (LFS)
時間枠:5 years

LFS defined as the time from first dose to the date of leukemic transformation or death, whichever occurs first.

5 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年8月13日

一次修了 (推定)

2029年12月31日

研究の完了 (推定)

2029年12月31日

試験登録日

最初に提出

2024年5月2日

QC基準を満たした最初の提出物

2024年5月2日

最初の投稿 (実際)

2024年5月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CDAK539A12001B
  • CNST0610C210 (その他の識別子:Constellation Pharmaceuticals)
  • 2023-508950-24-00 (レジストリ識別子:EU CT Number)
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。